News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
Events Partner Content STING & TLR Targeting Therapies Summit Investigating the cGAS-STING and TLR pathways
News New data could widen use of Novartis' SMA therapy Zolgensma Phase 3 results with an intrathecal version of Novartis spinal muscular atrophy (SMA) gene therapy could make older children eligible for treatment.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
